Abpro Holdings (ABPO) Accumulated Expenses (2021 - 2026)
Abpro Holdings' (ABPO) quarterly Accumulated Expenses came in at $3.9 million in Q1 2026, down 50.23% YoY from $7.8 million in Q1 2025, and little changed on a QoQ basis from $3.9 million in Q4 2025.
Abpro Holdings (ABPO) Accumulated Expenses (2021 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 6 years of Accumulated Expenses data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Accumulated Expenses fell 50.23% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 50.23% YoY) and the FY2025 annual result came in at $3.9 million, down 48.31% from the prior year.
- Accumulated Expenses held at $3.9 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $8.0 million in Q3 2025 to a low of $200000.0 in Q2 2024.
- A 5-year average of $3.6 million and a median of $2.8 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 289749.41% — and 2024, when it slumped 88.86%.
- Tracing ABPO's Accumulated Expenses over 5 years: stood at $5.2 million in 2022, then sank by 73.1% to $1.4 million in 2023, then jumped by 436.19% to $7.5 million in 2024, then slumped by 48.31% to $3.9 million in 2025, then dropped by 0.1% to $3.9 million in 2026.
- The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $3.9 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.87 Mn |
| Dec 31, 2025 | 3.88 Mn |
| Sep 30, 2025 | 8.03 Mn |
| Jun 30, 2025 | 8.02 Mn |
| Mar 31, 2025 | 7.78 Mn |
| Dec 31, 2024 | 7.50 Mn |
| Sep 30, 2024 | 6.05 Mn |
| Jun 30, 2024 | 200,000.00 |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 715,146.00 |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Dec 31, 2022 | 5.20 Mn |
| Sep 30, 2022 | 895,709.00 |
| Jun 30, 2022 | 576,758.00 |
| Mar 31, 2022 | 303,037.00 |
| Dec 31, 2021 | 1,793.00 |